KR101766936B1 - 항체 제제 및 치료 요법 - Google Patents

항체 제제 및 치료 요법 Download PDF

Info

Publication number
KR101766936B1
KR101766936B1 KR1020127021299A KR20127021299A KR101766936B1 KR 101766936 B1 KR101766936 B1 KR 101766936B1 KR 1020127021299 A KR1020127021299 A KR 1020127021299A KR 20127021299 A KR20127021299 A KR 20127021299A KR 101766936 B1 KR101766936 B1 KR 101766936B1
Authority
KR
South Korea
Prior art keywords
psoriasis
dose
polysorbate
administration
glutamic acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020127021299A
Other languages
English (en)
Korean (ko)
Other versions
KR20120118036A (ko
Inventor
딩지앙 리우
홀리 주오홍 후앙
데이비드 앤드류 마틴
크리스토퍼 보이드 러셀
데이비드 에이치. 샐린저
스콧 월터 바움가트너
크리스토퍼 제이. 엔드레스
Original Assignee
키린-암젠, 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43858045&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR101766936(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 키린-암젠, 인코포레이티드 filed Critical 키린-암젠, 인코포레이티드
Publication of KR20120118036A publication Critical patent/KR20120118036A/ko
Application granted granted Critical
Publication of KR101766936B1 publication Critical patent/KR101766936B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0021—Intradermal administration, e.g. through microneedle arrays, needleless injectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Dermatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Endocrinology (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Reproductive Health (AREA)
  • Transplantation (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
KR1020127021299A 2010-01-15 2011-01-12 항체 제제 및 치료 요법 Active KR101766936B1 (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US29538710P 2010-01-15 2010-01-15
US61/295,387 2010-01-15
US42205910P 2010-12-10 2010-12-10
US61/422,059 2010-12-10
PCT/US2011/020985 WO2011088120A1 (en) 2010-01-15 2011-01-12 Antibody formulation and therapeutic regimens

Publications (2)

Publication Number Publication Date
KR20120118036A KR20120118036A (ko) 2012-10-25
KR101766936B1 true KR101766936B1 (ko) 2017-08-09

Family

ID=43858045

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020127021299A Active KR101766936B1 (ko) 2010-01-15 2011-01-12 항체 제제 및 치료 요법

Country Status (38)

Country Link
US (5) US8883151B2 (enExample)
EP (3) EP2523688B1 (enExample)
JP (2) JP5743234B2 (enExample)
KR (1) KR101766936B1 (enExample)
CN (1) CN102821787B (enExample)
AR (1) AR079903A1 (enExample)
AU (3) AU2011205402B2 (enExample)
BR (1) BR112012017150B1 (enExample)
CA (1) CA2787128C (enExample)
CL (1) CL2012001966A1 (enExample)
CO (1) CO6640206A2 (enExample)
CR (1) CR20120419A (enExample)
CY (2) CY1119852T1 (enExample)
DK (2) DK2523688T3 (enExample)
EA (2) EA201891433A3 (enExample)
ES (2) ES2753216T3 (enExample)
HR (1) HRP20171939T1 (enExample)
HU (2) HUE035618T2 (enExample)
IL (1) IL220602B (enExample)
IN (1) IN2012DN06720A (enExample)
LT (2) LT3295957T (enExample)
MA (1) MA33989B1 (enExample)
MX (1) MX349856B (enExample)
MY (1) MY182680A (enExample)
NO (1) NO2523688T3 (enExample)
NZ (1) NZ601125A (enExample)
PE (1) PE20121691A1 (enExample)
PH (1) PH12012501364A1 (enExample)
PL (2) PL2523688T3 (enExample)
PT (2) PT2523688T (enExample)
RS (2) RS59743B1 (enExample)
SG (2) SG182468A1 (enExample)
SI (2) SI2523688T1 (enExample)
TN (1) TN2012000335A1 (enExample)
TW (1) TWI554282B (enExample)
UA (1) UA112288C2 (enExample)
WO (1) WO2011088120A1 (enExample)
ZA (1) ZA201205167B (enExample)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7767206B2 (en) 2006-10-02 2010-08-03 Amgen Inc. Neutralizing determinants of IL-17 Receptor A and antibodies that bind thereto
JO3244B1 (ar) 2009-10-26 2018-03-08 Amgen Inc بروتينات ربط مستضادات il – 23 البشرية
EP2523688B1 (en) 2010-01-15 2017-10-11 Kirin-Amgen, Inc. Antibody formulation and therapeutic regimens
DK2531218T3 (en) * 2010-02-04 2019-04-01 Csl Behring Ag immunoglobulin
RU2012149227A (ru) 2010-05-20 2014-06-27 Аблинкс Нв Биологические материалы, относящиеся к her3
EP2725034B1 (en) * 2010-09-22 2019-04-03 Amgen Inc. Carrier immunoglobulins with no specificity for human tissues and uses thereof
EP3058952A1 (en) * 2011-04-07 2016-08-24 Glaxosmithkline LLC Formulations with reduced viscosity
UA117218C2 (uk) 2011-05-05 2018-07-10 Мерк Патент Гмбх Поліпептид, спрямований проти il-17a, il-17f та/або il17-a/f
JOP20200043A1 (ar) * 2011-05-10 2017-06-16 Amgen Inc طرق معالجة أو منع الاضطرابات المختصة بالكوليسترول
WO2013016220A1 (en) * 2011-07-22 2013-01-31 Amgen Inc. Il-17 receptor a is required for il-17c biology
WO2013078375A2 (en) * 2011-11-23 2013-05-30 Amgen Inc. Administration of alpha4beta7 hetero-dimer-specific antibody
MY167233A (en) * 2012-03-07 2018-08-14 Lilly Co Eli Il-17 antibody formulation
CN104271600B (zh) 2012-05-14 2018-09-14 诺和诺德股份有限公司 稳定化的蛋白溶液
HK1219425A1 (zh) 2013-03-15 2017-04-07 Amgen Inc. 使用抗il-23抗体治疗银屑病的方法
CN105307675A (zh) 2013-03-15 2016-02-03 美国安进公司 使用抗il23抗体治疗克罗恩氏病的方法
WO2015153144A1 (en) 2014-03-31 2015-10-08 Kirin-Amgen, Inc. Methods of treating nail and scalp psoriasis
CA2949237C (en) 2014-05-16 2022-08-23 Amgen Inc. Assay for detecting th1 and th2 cell populations
KR102427097B1 (ko) 2014-08-26 2022-08-01 암젠 케이-에이, 인크. 항-tnf-알파 항체 요법을 받은 건선 환자의 치료 방법
JP6795397B2 (ja) * 2014-09-10 2020-12-02 日油株式会社 蛋白質吸着抑制剤及び蛋白質吸着抑制方法
JP6726666B2 (ja) 2014-12-03 2020-07-22 ツェー・エス・エル・ベーリング・アクチエンゲゼルシャフト 免疫グロブリンを含む安定性が高められた医薬製品
AR103173A1 (es) 2014-12-22 2017-04-19 Novarits Ag Productos farmacéuticos y composiciones líquidas estables de anticuerpos il-17
JP6909208B2 (ja) 2015-09-17 2021-07-28 アムジェン インコーポレイテッド Ｉｌ２３経路バイオマーカーを使用するｉｌ２３アンタゴニストに対する臨床応答の予測
HK1255922A1 (zh) 2015-11-04 2019-09-06 Astrazeneca Ab 二肽基肽酶-4和骨膜素作为嗜酸性粒细胞疾病中嗜酸性粒细胞靶向治疗药物临床反应的预测因子
AU2016379157A1 (en) 2015-12-22 2018-06-21 Amgen Inc. CCL20 as a predictor of clinical response to IL23-antagonists
EP3446178A4 (en) 2016-04-19 2020-01-22 Sage Electrochromics, Inc. ELECTROCHROMIC DEVICE COMPRISING A TRANSPARENT CONDUCTIVE OXIDE LAYER AND AN OMNIBUS BAR AND ITS FORMING METHOD
GB201612043D0 (en) * 2016-07-11 2016-08-24 Crescendo Biologics Ltd Composition for treatment of disorders
CA2974531A1 (en) * 2017-07-26 2019-01-26 Michael Giroux Safety anchor and roof vent
GB201719447D0 (en) 2017-11-23 2018-01-10 Ucb Biopharma Sprl Pharmaceutical composition
EA202190197A1 (ru) 2018-07-13 2021-04-26 Астразенека Коллаборэйшн Венчерз, Ллс Лечение язвенного колита с помощью бразикумаба
KR102735988B1 (ko) 2019-02-18 2024-12-03 일라이 릴리 앤드 캄파니 치료 항체 제제
WO2021050563A1 (en) * 2019-09-09 2021-03-18 The Rockefeller University Antibody treatment for lesional tissue of hidradenitis suppurativa
US20220380449A1 (en) * 2019-09-11 2022-12-01 Bausch Health Ireland Limited Methods of treating nonalcoholic fatty liver disease (nafld) using il-17ra antibody
MX2022010120A (es) * 2020-02-18 2022-09-05 Amgen Inc Formulaciones de anticuerpos anti-tslp humanos y metodos de uso de los mismos.
CN112891531B (zh) * 2020-06-19 2021-10-08 北京东方百泰生物科技股份有限公司 一种抗il-17ra单克隆抗体的注射制剂
KR20240021800A (ko) * 2021-05-12 2024-02-19 아납티스바이오, 아이엔씨. 항체 조성물
EP4537345A1 (en) * 2022-06-06 2025-04-16 Fusion Pharmaceuticals Inc. Methods of dosing therapeutic agents

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007092772A2 (en) 2006-02-03 2007-08-16 Medimmune, Inc. Protein formulations
WO2008079290A2 (en) * 2006-12-21 2008-07-03 Amgen Inc Stable buffered formulations containing polypeptides
EP1977763A1 (en) 2005-12-28 2008-10-08 Chugai Seiyaku Kabushiki Kaisha Antibody-containing stabilizing preparation

Family Cites Families (96)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1000835A (en) 1911-06-19 1911-08-15 Stewart A Minnick Calipers.
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
IL98078A0 (en) 1991-05-07 1992-06-21 Yeda Res & Dev Pharmaceutical compositions comprising an anticytokyne
IL83878A (en) 1987-09-13 1995-07-31 Yeda Res & Dev Soluble protein corresponding to tnf inhibitory protein its preparation and pharmaceutical compositions containing it
US5204244A (en) 1987-10-27 1993-04-20 Oncogen Production of chimeric antibodies by homologous recombination
GB8807803D0 (en) 1988-03-31 1988-05-05 Glaxo Group Ltd Biochemical product
AU631545B2 (en) 1988-04-15 1992-12-03 Protein Design Labs, Inc. Il-2 receptor-specific chimeric antibodies
IL94039A (en) 1989-08-06 2006-09-05 Yeda Res & Dev Antibodies to tbp - 1 and their use
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5116964A (en) 1989-02-23 1992-05-26 Genentech, Inc. Hybrid immunoglobulins
ES2238070T3 (es) 1989-04-21 2005-08-16 Amgen Inc. Receptor del tnf, proteina ligante del tnf y adn codante para estos.
DE3922089A1 (de) 1989-05-09 1990-12-13 Basf Ag Neue proteine und ihre herstellung
AU636608B2 (en) 1989-05-18 1993-05-06 Yeda Research And Development Co. Ltd. Tumor necrosis factor binding protein II, it's purification and antibodies thereto
IL95031A (en) 1989-07-18 2007-03-08 Amgen Inc Method for the production of a human recombinant tumor necrosis factor inhibitor
US5703088A (en) 1989-08-21 1997-12-30 Beth Israel Deaconess Medical Center, Inc. Topical application of spiperone or derivatives thereof for treatment of pathological conditions associated with immune responses
AU630497B2 (en) 1989-09-05 1992-10-29 Immunex Corporation Tumor necrosis factor-alpha and -beta receptors
US5395760A (en) 1989-09-05 1995-03-07 Immunex Corporation DNA encoding tumor necrosis factor-α and -β receptors
EP1132471A3 (de) 1989-09-12 2001-11-28 F. Hoffmann-La Roche Ag TNF-bindende Proteine
JPH03127800A (ja) 1989-10-13 1991-05-30 Teijin Ltd 腫瘍壊死因子活性抑制物質
EP0433900B1 (en) 1989-12-13 1995-09-20 Yeda Research And Development Company Limited Expression of the recombinant tumor necrosis factor binding protein I (TBP-I)
EP1690935A3 (en) 1990-01-12 2008-07-30 Abgenix, Inc. Generation of xenogeneic antibodies
US6673986B1 (en) 1990-01-12 2004-01-06 Abgenix, Inc. Generation of xenogeneic antibodies
US5136021A (en) 1990-02-27 1992-08-04 Health Research, Inc. TNF-inhibitory protein and a method of production
US6552170B1 (en) 1990-04-06 2003-04-22 Amgen Inc. PEGylation reagents and compounds formed therewith
US6458360B1 (en) 1990-04-25 2002-10-01 The Johns Hopkins University Soluble complement regulatory molecules
GB2243569A (en) 1990-05-02 1991-11-06 Andrew Langdon Brush with timer
DE10075010I2 (de) 1990-06-28 2004-01-29 Hoechst Ag Fusionsproteine mit immunglobulinanteilen, ihre Herstellung und Verwendung.
WO1992001002A1 (en) 1990-07-11 1992-01-23 Teijin Limited Tumor necrosis factor activity inhibitor and production thereof
SG63617A1 (en) 1991-01-18 1999-03-30 Amgen Boulder Inc Methods for treating tumar necrosis factor mediated diseases
CA2106079C (en) 1991-03-15 2000-04-25 Robert C. Thompson Pegylation of polypeptides
IL99120A0 (en) 1991-08-07 1992-07-15 Yeda Res & Dev Multimers of the soluble forms of tnf receptors,their preparation and pharmaceutical compositions containing them
JP3122139B2 (ja) 1991-10-15 2001-01-09 マラーキー，ミッシェル，エフ． 後期段階炎症反応の治療用組成物
US5716805A (en) 1991-10-25 1998-02-10 Immunex Corporation Methods of preparing soluble, oligomeric proteins
EP1136556B1 (en) 1991-11-25 2005-06-08 Enzon, Inc. Method of producing multivalent antigen-binding proteins
NZ251820A (en) 1992-03-30 1996-07-26 Immunex Corp Fusion proteins with tnf-r (tumour necrosis factor-receptor) peptide linked to another tnf-r or an il-1r (interleukin-1-receptor) peptide
DE69327582T2 (de) 1992-04-30 2000-08-03 Amgen Inc., Thousand Oaks Methoden zur Behandlung von Interleukin- 1 und - Tumor - Nekrose - Faktor - verursachten Krankheiten
JPH05312248A (ja) 1992-05-08 1993-11-22 Nissan Motor Co Ltd シフトレバー装置
KR100232688B1 (ko) 1992-09-15 1999-12-01 스코트 쥐. 홀퀴스트 종양 괴사 인자 길항제를 함유하는 tnf-의존성 염증 치료용 제약 조성물
EP0672142B1 (en) 1992-12-04 2001-02-28 Medical Research Council Multivalent and multispecific binding proteins, their manufacture and use
US6562333B1 (en) 1993-06-14 2003-05-13 Schering Corporation Purified mammalian CTLA-8 antigens and related reagents
JP4373495B2 (ja) 1995-03-23 2009-11-25 イミュネックス・コーポレーション Ｉｌ−１７受容体
US6680057B1 (en) 1995-03-23 2004-01-20 Immunex Corporation Methods of treating autoimmune disease by administering interleukin-17 receptor
US6074849A (en) 1995-07-19 2000-06-13 Genetics Institute, Inc. Polynucleotides encoding human CTLA-8 related proteins
EP0839196B1 (en) 1995-07-19 2005-05-11 Genetics Institute, LLC Human ctla-8 and uses of ctla-8-related proteins
US6267958B1 (en) 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
TW555765B (en) 1996-07-09 2003-10-01 Amgen Inc Low molecular weight soluble tumor necrosis factor type-I and type-II proteins
US6406867B1 (en) 1996-08-16 2002-06-18 Human Genome Sciences, Inc. Antibody to human endokine alpha and methods of use
EP0959897B1 (en) 1996-11-27 2009-04-22 Immunex Corporation Method of regulating nitric oxide production
ES2301183T3 (es) 1996-12-03 2008-06-16 Amgen Fremont Inc. Anticuerpo completamente humano que se une al receptor del egfr.
US6171586B1 (en) 1997-06-13 2001-01-09 Genentech, Inc. Antibody formulation
US6482923B1 (en) 1997-09-17 2002-11-19 Human Genome Sciences, Inc. Interleukin 17-like receptor protein
AU9482498A (en) 1997-09-17 1999-04-05 Human Genome Sciences, Inc. Interleukin-17 receptor-like protein
PT1076703E (pt) 1998-05-15 2007-10-10 Genentech Inc ''utilizações terapêuticas de polipéptido homólogos de il-17''
JP2000247903A (ja) * 1999-03-01 2000-09-12 Chugai Pharmaceut Co Ltd 長期安定化製剤
US6833268B1 (en) 1999-06-10 2004-12-21 Abgenix, Inc. Transgenic animals for producing specific isotypes of human antibodies via non-cognate switch regions
ATE464062T1 (de) 1999-10-04 2010-04-15 Novartis Vaccines & Diagnostic Stabilisierte flüssige pharmazeutische zusammensetzung enthaltend tfpi
AR030554A1 (es) 2000-03-16 2003-08-27 Amgen Inc Moleculas similares a receptores il-17 y usos de las mismas
EP1266002A2 (en) 2000-03-16 2002-12-18 Amgen Inc., Il-17 receptor like molecules and uses thereof
US20030180255A1 (en) 2000-08-24 2003-09-25 Genentech, Inc. IL-17 homologous polypeptides and therapeutic uses thereof
US6793919B2 (en) 2000-10-18 2004-09-21 Immunex Corporation Methods for treating rheumatoid arthritis using IL-17 antagonists
EP1478394B1 (en) 2002-02-27 2008-07-30 Immunex Corporation Stabilized TNFR-Fc composition comprising arginine
WO2004002519A1 (en) 2002-06-27 2004-01-08 Smithkline Beecham Corporation Methods of treating or preventing ibd with il-18
DE60305919T2 (de) 2002-06-28 2007-01-18 Domantis Limited, Cambridge Dual-specifische liganden mit erhöhter halbwertszeit
DE10333317A1 (de) 2003-07-22 2005-02-17 Biotecon Therapeutics Gmbh Formulierung für Proteinarzneimittel ohne Zusatz von humanem Serumalbumin (HSA)
WO2005016273A2 (en) 2003-08-05 2005-02-24 3M Innovative Properties Company Infection prophylaxis using immune response modifier compounds
GB0321703D0 (en) * 2003-09-16 2003-10-15 Imerys Minerals Ltd Surface modified fillers for polymer resin compositions
WO2005063291A1 (ja) 2003-12-25 2005-07-14 Kirin Beer Kabushiki Kaisha 抗体を含有する安定な水性医薬製剤
IL159670A0 (en) 2003-12-31 2004-06-01 Yeda Res & Dev Use of il-18 binding protein in inflammations
JP2008501826A (ja) 2004-06-04 2008-01-24 デジグナー モレキュールズ インコーポレイテッド フリーラジカル硬化可能なポリエステル類およびその使用方法
GB0425569D0 (en) 2004-11-19 2004-12-22 Celltech R&D Ltd Biological products
JP2008532493A (ja) 2005-02-14 2008-08-21 ワイス Ｉｌ−１７ｆとｉｌ−１７ｒとの間の相互作用の特性解析
JP2008543839A (ja) 2005-06-14 2008-12-04 アムジェン インコーポレーテッド 自己緩衝タンパク質製剤
EA014513B1 (ru) 2005-08-03 2010-12-30 Иммьюноджен, Инк. Композиция иммуноконъюгата
US7790679B2 (en) 2005-08-05 2010-09-07 Amgen Inc. Pharmaceutical formulations
EP2116258A1 (en) 2005-09-01 2009-11-11 Schering Corporation Use of IL-23 and IL-17 antagonists to treat autoimmune ocular inflammatory disease
EP1931708A1 (en) 2005-10-18 2008-06-18 Zymogenetics, Inc. Il-17c antagonists and methods of using the same
KR20110128957A (ko) 2005-11-01 2011-11-30 와이어쓰 엘엘씨 약물 재구성 또는 희석을 위한 염화나트륨 용액
US7767206B2 (en) 2006-10-02 2010-08-03 Amgen Inc. Neutralizing determinants of IL-17 Receptor A and antibodies that bind thereto
UA99716C2 (ru) * 2006-10-02 2012-09-25 Кирин-Амген Инк. Антитело, которое специфично связывает человеческий il-17 рецептор а (il-17ra)
CA2666842A1 (en) 2006-10-18 2008-04-24 Zymogenetics, Inc. Il-17c antagonists and methods of using the same
FR2910324B1 (fr) 2006-12-21 2009-03-06 Biomerieux Sa Nouveau medicament pour le traitement d'un cancer gastrique
GB0700523D0 (en) 2007-01-11 2007-02-21 Insense Ltd The Stabilisation Of Proteins
CA2679588A1 (en) 2007-03-26 2008-10-02 Zymogenetics, Inc. Soluble il-17ra/rc fusion proteins and related methods
EP2170958A1 (en) * 2007-06-13 2010-04-07 Amgen Inc. Il-17 heteromeric receptor complex
US20110014676A1 (en) 2007-06-29 2011-01-20 Battelle Memorial Institute Protein stabilization
CA2696049A1 (en) 2007-08-17 2009-02-26 Amgen Inc. Formulations of antibodies and fc-fusion molecules using polycations
CN104151428B (zh) 2008-02-21 2017-07-14 麒麟-安姆根有限公司 Il‑17ra‑il‑17rb拮抗物及其用途
TW201117824A (en) 2009-10-12 2011-06-01 Amgen Inc Use of IL-17 receptor a antigen binding proteins
EP2523688B1 (en) 2010-01-15 2017-10-11 Kirin-Amgen, Inc. Antibody formulation and therapeutic regimens
JP5537740B2 (ja) 2010-10-08 2014-07-02 ノバルティス アーゲー Ｉｌ−１７アンタゴニストを用いて乾癬を治療する方法
WO2012061129A1 (en) 2010-10-25 2012-05-10 Genentech, Inc Treatment of gastrointestinal inflammation and psoriasis a
US20140044727A1 (en) * 2011-04-07 2014-02-13 Glaxosmithkline Llc Formulations with reduced viscosity
EP3058952A1 (en) * 2011-04-07 2016-08-24 Glaxosmithkline LLC Formulations with reduced viscosity
WO2013016220A1 (en) 2011-07-22 2013-01-31 Amgen Inc. Il-17 receptor a is required for il-17c biology
WO2015153144A1 (en) 2014-03-31 2015-10-08 Kirin-Amgen, Inc. Methods of treating nail and scalp psoriasis
KR102427097B1 (ko) 2014-08-26 2022-08-01 암젠 케이-에이, 인크. 항-tnf-알파 항체 요법을 받은 건선 환자의 치료 방법

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1977763A1 (en) 2005-12-28 2008-10-08 Chugai Seiyaku Kabushiki Kaisha Antibody-containing stabilizing preparation
WO2007092772A2 (en) 2006-02-03 2007-08-16 Medimmune, Inc. Protein formulations
WO2008079290A2 (en) * 2006-12-21 2008-07-03 Amgen Inc Stable buffered formulations containing polypeptides

Also Published As

Publication number Publication date
CO6640206A2 (es) 2013-03-22
CA2787128C (en) 2019-06-11
US20150017184A1 (en) 2015-01-15
JP5743234B2 (ja) 2015-07-01
WO2011088120A8 (en) 2012-09-13
MX2012008213A (es) 2012-11-06
PT3295957T (pt) 2019-11-12
ES2652637T3 (es) 2018-02-05
PL3295957T3 (pl) 2020-03-31
EA201891433A2 (ru) 2018-11-30
SI2523688T1 (en) 2018-03-30
US20130022621A1 (en) 2013-01-24
NZ601125A (en) 2014-08-29
EA201290653A1 (ru) 2013-02-28
DK3295957T3 (da) 2019-10-14
EP2523688B1 (en) 2017-10-11
CL2012001966A1 (es) 2013-01-18
LT2523688T (lt) 2018-03-12
US8883151B2 (en) 2014-11-11
EA031209B1 (ru) 2018-12-28
EA201891433A3 (ru) 2019-02-28
SG182468A1 (en) 2012-08-30
ZA201205167B (en) 2013-03-27
MA33989B1 (fr) 2013-02-01
US11505612B2 (en) 2022-11-22
US10808033B2 (en) 2020-10-20
HRP20171939T1 (hr) 2018-03-23
PL2523688T3 (pl) 2018-04-30
CY1122466T1 (el) 2020-10-14
AU2011205402B2 (en) 2015-02-05
RS56781B1 (sr) 2018-04-30
SI3295957T1 (sl) 2020-02-28
AR079903A1 (es) 2012-02-29
MY182680A (en) 2021-01-29
US20230192873A1 (en) 2023-06-22
EP3295957B1 (en) 2019-08-07
JP2013517277A (ja) 2013-05-16
US10072085B2 (en) 2018-09-11
HUE046670T2 (hu) 2020-03-30
ES2753216T3 (es) 2020-04-07
EP3295957A1 (en) 2018-03-21
CN102821787A (zh) 2012-12-12
TWI554282B (zh) 2016-10-21
BR112012017150A2 (pt) 2017-10-10
HUE035618T2 (en) 2018-05-28
AU2017216579A1 (en) 2017-09-07
TN2012000335A1 (en) 2013-12-12
AU2015202023B2 (en) 2017-05-18
IN2012DN06720A (enExample) 2015-10-23
MX349856B (es) 2017-08-16
KR20120118036A (ko) 2012-10-25
TW201129382A (en) 2011-09-01
US20200399384A1 (en) 2020-12-24
JP2015052017A (ja) 2015-03-19
RS59743B1 (sr) 2020-02-28
AU2011205402A1 (en) 2012-07-12
CR20120419A (es) 2012-11-29
CY1119852T1 (el) 2018-06-27
UA112288C2 (uk) 2016-08-25
AU2015202023A1 (en) 2015-05-14
DK2523688T3 (en) 2017-12-04
CN102821787B (zh) 2015-07-29
CA2787128A1 (en) 2011-07-21
LT3295957T (lt) 2020-01-27
BR112012017150B1 (pt) 2022-03-03
EP3632466A1 (en) 2020-04-08
SG10201604093XA (en) 2016-07-28
WO2011088120A1 (en) 2011-07-21
PT2523688T (pt) 2018-01-05
EP2523688A1 (en) 2012-11-21
IL220602B (en) 2019-03-31
PE20121691A1 (es) 2012-12-14
US20180346583A1 (en) 2018-12-06
PH12012501364A1 (en) 2012-10-22
EA031209B9 (ru) 2021-11-19
NO2523688T3 (enExample) 2018-03-10
WO2011088120A9 (en) 2012-08-09

Similar Documents

Publication Publication Date Title
KR101766936B1 (ko) 항체 제제 및 치료 요법
JP2018507202A (ja) モノクローナル抗体のための安定的な液体製剤
JP2021517566A (ja) 汎発性膿疱性乾癬の処置のための抗ｉｌ−３６ｒ抗体の使用
CN112312971A (zh) 结合cd123和cd3的双特异性抗体的给药
CN112512578A (zh) 结合cd123和cd3的双特异性抗体的给药
RU2823427C2 (ru) Дозировка и схема введения для лечения или предупреждения связанных с с5 заболеваний посредством применения антитела против с5 кровалимаба
AU2013202140A1 (en) Antibody formulation and therapeutic regimens
TW202146452A (zh) 結合ｃｄ１２３和ｃｄ３之雙特異性抗體的給藥
EA040869B1 (ru) Фармацевтический состав для лечения воспалительных заболеваний

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

PN2301 Change of applicant

St.27 status event code: A-3-3-R10-R13-asn-PN2301

St.27 status event code: A-3-3-R10-R11-asn-PN2301

A201 Request for examination
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

P22-X000 Classification modified

St.27 status event code: A-2-2-P10-P22-nap-X000

P22-X000 Classification modified

St.27 status event code: A-2-2-P10-P22-nap-X000

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000

S14-X000 Exclusive voluntary license recorded

St.27 status event code: A-4-4-S10-S14-lic-X000

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 5

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 6

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 7

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 8

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 9

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-OTH-PR1001 (AS PROVIDED BY THE NATIONAL OFFICE)

Year of fee payment: 9